Literature DB >> 15153030

Iron-catalyzed cross-coupling reactions. A scalable synthesis of the immunosuppressive agent FTY720.

Günter Seidel1, Daniel Laurich, Alois Fürstner.   

Abstract

A chemo- and regioselective cross-coupling reaction of the functionalized aryl triflate 5 with octylmagnesium bromide catalyzed by cheap, nontoxic, and environmentally benign Fe(acac)(3) sets the basis for a practical and scaleable synthesis of the octylbenzene derivative 6, which serves as a key building block for the preparation of FTY720 (1). This 2-amino-1,3-propanediol derivative shows highly promising immunosuppressive properties and is currently in human clinical phase III trials.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15153030     DOI: 10.1021/jo049885d

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  11 in total

1.  PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Authors:  Paolo Neviani; Jason G Harb; Joshua J Oaks; Ramasamy Santhanam; Christopher J Walker; Justin J Ellis; Gregory Ferenchak; Adrienne M Dorrance; Carolyn A Paisie; Anna M Eiring; Yihui Ma; Hsiaoyin C Mao; Bin Zhang; Mark Wunderlich; Philippa C May; Chaode Sun; Sahar A Saddoughi; Jacek Bielawski; William Blum; Rebecca B Klisovic; Janelle A Solt; John C Byrd; Stefano Volinia; Jorge Cortes; Claudia S Huettner; Steffen Koschmieder; Tessa L Holyoake; Steven Devine; Michael A Caligiuri; Carlo M Croce; Ramiro Garzon; Besim Ogretmen; Ralph B Arlinghaus; Ching-Shih Chen; Robert Bittman; Peter Hokland; Denis-Claude Roy; Dragana Milojkovic; Jane Apperley; John M Goldman; Alistair Reid; James C Mulloy; Ravi Bhatia; Guido Marcucci; Danilo Perrotti
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

2.  The N-Methylpyrrolidone (NMP) Effect in Iron-Catalyzed Cross-Coupling with Simple Ferric Salts and MeMgBr.

Authors:  Salvador B Muñoz; Stephanie L Daifuku; Jeffrey D Sears; Tessa M Baker; Stephanie H Carpenter; William W Brennessel; Michael L Neidig
Journal:  Angew Chem Int Ed Engl       Date:  2018-05-08       Impact factor: 15.336

Review 3.  Advances in transition metal (Pd, Ni, Fe)-catalyzed cross-coupling reactions using alkyl-organometallics as reaction partners.

Authors:  Ranjan Jana; Tejas P Pathak; Matthew S Sigman
Journal:  Chem Rev       Date:  2011-02-14       Impact factor: 60.622

4.  Identification of potent tricyclic prodrug S1P1 receptor modulators.

Authors:  David Marcoux; Hai-Yun Xiao; T G Murali Dhar; Jenny Xie; Lois D Lehman-McKeeman; Dauh-Rurng Wu; Marta Dabros; Xiaoxia Yang; Tracy L Taylor; Xia D Zhou; Elizabeth M Heimrich; Rochelle Thomas; Kim W McIntyre; Hong Shi; Paul C Levesque; Huadong Sun; Zheng Yang; Anthony M Marino; Georgia Cornelius; Celia J D'Arienzo; Anuradha Gupta; Bala Pragalathan; Richard Rampulla; Arvind Mathur; Ding Ren Shen; Mary Ellen Cvijic; Luisa Salter-Cid; Louis J Lombardo; Percy H Carter; Alaric J Dyckman
Journal:  Medchemcomm       Date:  2016-11-25       Impact factor: 3.597

5.  Quantitative geometric descriptions of the belt iron atoms of the iron-molybdenum cofactor of nitrogenase and synthetic iron(II) model complexes.

Authors:  Javier Vela; Jordi Cirera; Jeremy M Smith; Rene J Lachicotte; Christine J Flaschenriem; Santiago Alvarez; Patrick L Holland
Journal:  Inorg Chem       Date:  2007-01-08       Impact factor: 5.165

6.  The Effect of β-Hydrogen Atoms on Iron Speciation in Cross-Couplings with Simple Iron Salts and Alkyl Grignard Reagents.

Authors:  Jeffrey D Sears; Salvador B Muñoz; Stephanie L Daifuku; Ari A Shaps; Stephanie H Carpenter; William W Brennessel; Michael L Neidig
Journal:  Angew Chem Int Ed Engl       Date:  2019-01-29       Impact factor: 15.336

7.  Iron-catalyzed alkylations of aryl sulfamates and carbamates.

Authors:  Amanda L Silberstein; Stephen D Ramgren; Neil K Garg
Journal:  Org Lett       Date:  2012-07-03       Impact factor: 6.005

8.  FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.

Authors:  Qing Liu; Xiaobin Zhao; Frank Frissora; Yihui Ma; Ramasamy Santhanam; David Jarjoura; Amy Lehman; Danilo Perrotti; Ching-Shih Chen; James T Dalton; Natarajan Muthusamy; John C Byrd
Journal:  Blood       Date:  2007-08-29       Impact factor: 22.113

9.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

10.  FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology.

Authors:  Kunitomo Adachi; Kenji Chiba
Journal:  Perspect Medicin Chem       Date:  2007-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.